Former Novartis CEO Joe Jimenez and research leader Mark Fishman are fundraising again for their life sciences firm Aditum Bio, which in-licenses translational-stage drugs and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.